2.8 C
New York
Tuesday, January 31, 2023

Is Alaunos Therapeutics Inc. (NASDAQ: TCRT) Still On The Rise?

After Hours

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Alaunos Therapeutics Inc. (TCRT) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.0073, or -0.92%, to $0.79. The Alaunos Therapeutics Inc. has recorded 2,906 volume in the after hours trading session. Yahoo Finance discussed the stock recently as it posted Alaunos Therapeutics Highlights Strategic Priorities and Anticipated Portfolio Milestones for 2023.


Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored

Stocks Info

This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $0.80 and fluctuated between $0.8198 as its day high and $0.7417 as its day low. The current market capitalization of Alaunos Therapeutics Inc. is $191.87M. A total of 0.82 million shares were traded on the day, compared to an average of 1.70M shares.

Insider trades can also provide insight into a stock’s future direction. During the recent three months, TCRT has seen 2 BUY and 0 SELL insider trades, representing the acquisition of 2,000,000 and the disposition of 0 shares. Over the last 12 months, there were 11 BUYs and 1 SELLs from insiders. Insiders purchased 2,440,000 shares during that period but sold 18,750.

In the most recent transaction, Postma Robert W bought 750,000 shares of TCRT for 0.65 per share on Nov 29. After the transaction, the Director now owns 5,000,000 company shares. In a previous transaction on Nov 29, Vieser Jaime bought 1,250,000 shares at 0.65 per share. TCRT shares that Director owns now total 1,250,000.

Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for TCRT in the last 3 months, the mean price target is $3.75 with high estimates of $7.50 and low estimates of $1.25. In terms of 52-week highs and lows, TCRT has a high of $4.01 and a low of $0.41.

As of this writing, TCRT has an earnings estimate of -$0.08 per share for the current quarter. EPS was calculated based on a consensus of 5 estimates, with a high estimate of -$0.05 per share and a lower estimate of -$0.17. The company reported an EPS of -$0.05 in the last quarter, which was 28.60% higher than expectations of -$0.07.

Balance Sheet Annually/Quarterly

In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 6 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for TCRT is Overweight with a score of 4.00. A total of 4 analysts rated the stock as Buy while 0 rated it as Overweight while 2 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles